New target cuts clot risk without bleeding danger
Blood clotting is normal and necessary after an injury. But with aging, the system misfires more often, producing dangerous clots.
Researchers have now found a new target. The protein LRP5, previously known for its role in the WNT signalling pathway (a system that controls cell division and differentiation), turns out to be directly involved in platelet activation. Platelets are small cell fragments that form clots to seal damage. The research demonstrates for the first time that LRP5 plays a direct role in arterial thrombus formation.
In preclinical models, both genetic deletion and pharmacological inhibition of LRP5 substantially reduced platelet activation and clot formation in arteries. The crucial difference from existing drugs such as aspirin and clopidogrel: the bleeding impact was considerably lower. The researchers describe this as a promising indication of a safer class of antithrombotic therapy.
Why existing drugs pose a dilemma
Antiplatelet drugs act on the same regulatory mechanisms that are also needed for normal wound healing. Reducing clotting ability also makes everyday cuts or surgery more dangerous. That dilemma is typical of many interventions targeting age-related problems: suppressing what goes wrong also suppresses what works correctly. The LRP5 mechanism appears to partly bypass that trade-off, although the findings are preliminary and confined to animal models.
Aging and abnormal clotting
With advancing age, the risk of unwanted blood clots increases, even without atherosclerosis (the build-up of plaques in artery walls). Changes in the platelets themselves make the system more prone to activation. Drugs that can steer this process more precisely are clinically relevant, particularly for people at elevated cardiovascular risk who are also vulnerable to bleeding complications. Whether LRP5 inhibition will ever play a role in clinical practice still needs to be established in human studies.
Search terms: LRP5 platelet activation thrombosis, WNT signalling pathway cardiovascular, antithrombotic therapy bleeding risk